Diethylpropion and mazindol: An end to the discussion?

• Tipo: Artigo em Revista Científica Internacional
• Data: 2017

Autores

Lucchetta, RC (Autor) Outra; Riveros, BS (Autor) Outra; Pontarolo, R (Autor) Outra; Radominski, RB (Autor) Outra; Otuki, MF (Autor) Outra; Fernandez Llimos, F (Autor) Outra; Correr, CJ (Autor) Outra

Revista

Título: Revista da Associacao Medica Brasileira

Vol. 63

Páginas: 203-206

ISSN: 0104-4230

Editora: Elsevier

Indexação

Scopus - 3 Citações

Outras Informações

ID Authenticus: P-00M-V3R

DOI: 10.1590/1806-9282.63.03.203

Abstract (EN): Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa - Agência Nacional de Vigilância Sanitáia) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.

Idioma: Inglês

Tipo (Avaliação Docente): Científica